Acquisition reinforces Lyric’s commitment to healthcare decision intelligence across the healthcare ecosystem
PHILADELPHIA & NASHVILLE, Tenn.–(BUSINESS WIRE)–Lyric, a trusted leader in healthcare decision intelligence for payment accuracy, today announced its acquisition of Concert, a precision health payment accuracy leader with proprietary technology for translating machine-readable policies into real-time decisions.
The acquisition advances Lyric’s mission to build the most innovative and impactful company in healthcare decision intelligence. By combining Concert’s proprietary capabilities with Lyric42, Lyric’s Healthcare Decision Intelligence Platform, the company extends its ability to serve clients at a time when advanced diagnostics such as genetic testing and the rapid development of new therapies are reshaping healthcare.
Health plans face urgent demands to manage rising costs and keep pace with rapidly evolving clinical evidence. To meet these demands, plans require solutions that bring policy, data, and decision-making together in the systems they and their providers already use. The combination of Concert’s policy intelligence with the Lyric42 platform delivers that solution to Lyric’s clients at a critical moment.
“Healthcare decision intelligence will define the next decade of this industry, and Lyric is built to lead it,” said Halsey Wise, Lyric CEO. “Healthcare is entering a new era where frontier capabilities are propelling precision diagnostics, personalized therapies, specialty medicines, novel treatment modalities, and rapidly evolving clinical evidence. These themes will all redefine patient care. By combining Concert’s evidence-based, precision medicine capabilities with Lyric’s AI-powered Healthcare Decision Intelligence Platform, we offer our clients critical insights and intelligence. On behalf of our health plan clients, we continue to innovate and activate Lyric42 to create the most unique and powerful decision intelligence platform in the marketplace.”
Concert brings to Lyric a proprietary approach for building machine-readable clinical policy, developed over more than a decade of work in precision health payment accuracy.
“Concert was built on the conviction that clinical and administrative policy should be transparent, evidence-based, and computable, delivered into the systems that health plans and providers actually use to make decisions,” said Rob Metcalf, CEO, Concert. “Combining with Lyric allows us to deliver at scale through the Lyric42 platform. Together, we can extend intelligence across the workflows where healthcare decisions are made.”
Lyric and Concert have worked together since 2023, with the scope and impact of the joint solution growing nearly tenfold over that time. Today, the Diagnostics Module provides a policy and claim editing solution for all outpatient laboratory testing, and further scope expansions are planned. The acquisition extends that growing value across Lyric’s client base. “This combination allows us to accelerate our pace of innovation for our clients,” said Ravi Umarji, Lyric President and CFO. “Concert’s ground-up approach to synchronize human- and machine-readable policy will plug into health plan workflows through the Lyric42 platform. This approach fundamentally shifts the model from reactive enforcement at disconnected checkpoints to shared standards, providing transparency and alignment across stakeholders. The combination will benefit our health plan clients, their network providers, and the members they serve.”
Through this acquisition, Lyric is positioned to address the most urgent demands facing health plans, including managing rising costs, keeping pace with rapidly evolving clinical evidence, and supporting member access to high-value care.
About Lyric
Lyric is the trusted leader in healthcare decision intelligence. Built on more than 35 years of proven results, Lyric combines responsible AI with clinical, payment, regulatory, and policy expertise to deliver transparent, auditable insights in milliseconds across real-time claims workflows. Lyric augments human decision-making so health plans can make faster, more accurate payments while maintaining full control. Today, Lyric supports 200 million lives, with nine of the top 10 U.S. health plans relying on its platform to reduce waste, improve efficiency, and support accurate payments. To learn more, visit lyric.ai.
About Concert
Concert is a healthcare technology company enabling cost-effective access to diagnostics and therapeutics by harmonizing evidence, policy, and payment. Founded in 2010 to bring transparency and efficiency to genetic testing, Concert now offers the definitive precision health payment accuracy platform. The company combines proprietary market data, clinical and coding expertise, and patented technology to support diagnostic test ordering, resulting, coding, coverage, claim editing, and payment integrity. Since 2024, the company has operated under its abbreviated name, Concert. To learn more, visit concert.co.
Contacts
Media Contact
Courtney Merolle PR / Communications, Bospar [email protected]
